Marinomed extends the range of Marinosolv® applications

Marinomed Biotech AG, a globally active biopharmaceutical company based in Vienna, has achieved promising results for further areas of application with its Marinosolv®technology platform in preclinical studies.
By: PR&D
 
 
Spread the Word
Listed Under

Tag:
Marinomed

Industry:
Health

Location:
Vienna - Vienna - Austria

VIENNA - March 9, 2020 - PRLog -- ·       Preclinical studies show promising results with new compounds like mometasone, fluticasone and fluorometholone

·       Potential for developments in allergy, asthma, and ophthalmology

·       Marinosolv®facilitates the combination of active ingredients

Vienna (Austria), March 9th2020.
Marinomed Biotech AG, a globally active biopharmaceutical company based in Vienna, has achieved promising results for further areas of application with its Marinosolv®technology platform in preclinical studies. In addition to the lead products Budesolv (phase III study for allergic hay fever successfully completed) and Tacrosolv (phase II study for the treatment of allergic conjunctivitis and dry eye syndrome in preparation) the studies show that the poorly soluble compounds mometasone, fluticasone and fluorometholone can be dissolved in large quantities with the help of Marinosolv®. Compared to the current market products, Marinosolv®enabled a 50 to 200-fold improvement in solubility. "The new studies confirm that our clinically validated Marinosolv®platform has enormous potential to change therapies in the fields of asthma, allergies and ophthalmology", explains Marinomed CEO Andreas Grassauer.

The new substances are successfully used to treat various diseases such as asthma, inflammatory eye diseases and allergies, either individually or in combination with other drugs. Due to the local application in the eye, lungs or nose, Marinosolv®also offers crucial advantages for these active ingredients. Improved solubility results in higher amounts of the active ingredient at the target location with increased effectiveness even with reduced doses. This facilitates potential new developments especially for fluticasone for the treatment of allergies and asthma, either as monotherapy or in combination with compounds from the class of antihistamines or bronchodilators. Fluticasone as a modern steroid in ophthalmology would be another possible application. Furthermore, mometasone and fluorometholone are interesting alternatives to fluticasone. In addition, the preclinical studies show that Marinosolv®also supports the combination of different active ingredients. In the next step, Marinomed will examine the appropriate strategy for clinical trials and potential markets for these substances.

For further enquiries contact:

Dr. Eva Prieschl-Grassauer

Chief Scientific Officer, Marinomed

Veterinärplatz 1, 1210 Vienna, Austria

T +43 (0)1 250 77 4460

E-Mail: eva.prieschl@marinomed.com

http://www.marinomed.com


Roland Mayrl

Managing Partner, Metrum Communications

Bauernmarkt 10/19, 1010 Vienna, Austria

T +43 (0) 1 504 69 87 331

E-Mail: r.mayrl@metrum.at

http://www.metrum.at

Contact
PR&D
***@prd.at
End
Email:***@prd.at Email Verified
Tags:Marinomed
Industry:Health
Location:Vienna - Vienna - Austria
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
PR&D - Public Releations for Research & Education PRs
Trending News
Most Viewed
Top Daily News



Like PRLog?
9K2K1K
Click to Share